Vollum Institute, Oregon Health & Science University, Portland, OR, USA.
D. E. Shaw Research, New York, NY, USA.
Nature. 2018 Apr;556(7702):515-519. doi: 10.1038/s41586-018-0039-9. Epub 2018 Apr 18.
The NMDA (N-methyl-D-aspartate) receptor transduces the binding of glutamate and glycine, coupling it to the opening of a calcium-permeable ion channel . Owing to the lack of high-resolution structural studies of the NMDA receptor, the mechanism by which ion-channel blockers occlude ion permeation is not well understood. Here we show that removal of the amino-terminal domains from the GluN1-GluN2B NMDA receptor yields a functional receptor and crystals with good diffraction properties, allowing us to map the binding site of the NMDA receptor blocker, MK-801. This crystal structure, together with long-timescale molecular dynamics simulations, shows how MK-801 and memantine (a drug approved for the treatment of Alzheimer's disease) bind within the vestibule of the ion channel, promote closure of the ion channel gate and lodge between the M3-helix-bundle crossing and the M2-pore loops, physically blocking ion permeation.
NMDA(N-甲基-D-天冬氨酸)受体转导谷氨酸和甘氨酸的结合,将其与钙通透性离子通道的打开偶联。由于缺乏 NMDA 受体的高分辨率结构研究,离子通道阻断剂阻塞离子渗透的机制尚不清楚。在这里,我们表明,从 GluN1-GluN2B NMDA 受体中去除氨基末端结构域会产生具有功能的受体和具有良好衍射性质的晶体,从而使我们能够绘制 NMDA 受体阻断剂 MK-801 的结合位点。该晶体结构与长时间尺度的分子动力学模拟一起,显示了 MK-801 和美金刚(一种批准用于治疗阿尔茨海默病的药物)如何结合在离子通道的前庭内,促进离子通道门的关闭,并位于 M3-螺旋束交叉和 M2-孔环之间,物理上阻止离子渗透。